Connor, Clark & Lunn Investment Management Ltd. Fibrogen Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$0.89 - $2.36 $25,866 - $68,588	29,063 New	29,063 $25,000
Q3 2023 Nov 13, 2023	BUY	$0.79 - $2.83 $86,467 - $309,751	109,453 New	109,453 $94,000
Q1 2023 May 09, 2023	BUY	$15.95 - $25.18 $426,471 - $673,262	26,738 New	26,738 $498,000
Q2 2022 Aug 05, 2022	SELL	$7.94 - $12.96 $271,500 - $443,154	-34,194 Reduced 74.37%	11,783 $124,000
Q1 2022 May 12, 2022	SELL	$12.02 - $16.79 $244,679 - $341,777	-20,356 Reduced 30.69%	45,977 $553,000
Q4 2021 Feb 10, 2022	BUY	$9.93 - $15.39 $380,845 - $590,252	38,353 Added 137.07%	66,333 $935,000
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $112,529 - $294,478	11,054 Added 65.31%	27,980 $286,000
Q2 2021 Aug 12, 2021	SELL	$18.57 - $35.68 $318,828 - $612,589	-17,169 Reduced 50.36%	16,926 $451,000
Q1 2021 May 13, 2021	BUY	$31.0 - $55.72 $114,328 - $205,495	3,688 Added 12.13%	34,095 $1.18 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $1.13 Million - $1.49 Million	30,407 New	30,407 $1.13 Million
Q4 2019 Feb 12, 2020	SELL	$34.58 - $48.06 $402,857 - $559,899	-11,650 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$36.98 - $48.45 $430,816 - $564,442	11,650 New	11,650 $431,000

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

Primecap Management CO Pasadena, CA

9.91M
Shares

$3.47 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

6.8M
Shares

$2.38 Million
0.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.88M
Shares

$2.06 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.91M
Shares

$1.37 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.41M
Shares

$843,377
0.0% of portfolio

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account